| name | ata-ppgl-hypertensive-crisis-management |
| description | Administers intravenous phentolamine followed by infusion, then transitions to oral doxazosin after the acute phase resolves, while avoiding β-blockers before α-blockade. Indicated for severe hypertension (>180/110 mmHg) with headache, palpitations, or diaphoresis in known or suspected pheochromocytoma or paraganglioma. |
Manage hypertensive crisis in pheochromocytoma and paraganglioma
STEP 1 — Gather Information
Obtain blood pressure (target systolic >180 or diastolic >110 mmHg), assess for headache, palpitations, diaphoresis, and recent triggers (e.g., stress, medications, procedures). Confirm known or suspected PPGL via prior imaging, biochemical testing, or family history. Review current medications for contraindicated agents (e.g., β-blockers, metoclopramide, high-dose dexamethasone).
STEP 2 — Rule In / Rule Out
Is the patient experiencing a hypertensive crisis suggestive of catecholamine excess (SBP >180 or DBP >110 with acute symptoms) in the context of known or suspected PPGL?
- Yes: Proceed to Step 3.
- No: Consider alternative hypertensive emergencies and manage per standard protocols; do not initiate PPGL‑specific α‑blockade.
STEP 3 — Classify or Stratify
Classify as catecholamine‑driven hypertensive crisis requiring immediate α‑blockade. Assess for tachycardia or arrhythmia that may necessitate β‑blocker addition only after adequate α‑blockade is established.
STEP 4 — Decide
Administer intravenous phentolamine (Regitine®) 1–5 mg bolus, then start continuous infusion at 0.1–0.5 mg/min, titrating to achieve diastolic BP ≤110 mmHg (initial goal) and then reduce to ~160/100 mmHg within 2–6 hours. Once the acute phase resolves (stable BP for several hours), transition to oral doxazosin 1–2 mg daily, titrating up to 16 mg/day as needed. Avoid β‑blockers until sufficient α‑blockade is achieved; if tachycardia persists after α‑blockade, add a selective β‑blocker (e.g., atenolol) cautiously.
Clinical Guardrails / Mimics / Pitfalls
Do not administer β‑blockers before α‑blockade (risk of unopposed α‑mediated vasoconstriction and hypertensive crisis). Avoid monotherapy with β‑blockers (e.g., propranolol, labetalol, carvedilol) in this setting. Do not use high‑dose dexamethasone (>2 mg) as it can provoke crises. Refrain from giving metoclopramide or other dopamine antagonists that may trigger catecholamine release. Ensure phentolamine is available; if not, phenoxybenzamine is not approved in Japan, so phentolamine remains the injectable α‑blocker of choice.
Concrete Clinical Example
A 46‑year‑old man with a known left adrenal pheochromocytoma presents after intense emotional upset with BP 202/118 mmHg, throbbing headache, palpitations, and diaphoresis. He receives IV phentolamine 5 mg bolus, followed by infusion at 0.2 mg/min. After 4 hours his BP is 158/98 mmHg and symptoms abate. The infusion is tapered and oral doxazosin 2 mg at bedtime is started, titrated to 4 mg twice daily over the next day. No β‑blocker is given because heart rate remains 78 bpm.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165.
